[Asia Economy Reporter Yoo Hyun-seok] On the 3rd, Jinsystem, a field molecular diagnostic platform company, announced that it had received an order for about 30 diagnostic devices and 50,000 tests of COVID-19 diagnostic kits from Company A in India.


Jinsystem is making efforts to continuously supply products following this order. Through this, it plans to drive an expansion of market share within the Indian market.


Founded in 2010, Jinsystem is a company engaged in the rapid field molecular diagnostic platform business and possesses three core technologies related to molecular diagnostic platforms: precision hardware technology, High Multiplex technology, and biochip technology.


The company has proven the safety of its platform by commercializing core technologies and expanding globally since 2016 to countries including Japan, the United States, India, China, Europe, and the Middle East. Last year, it recorded sales exceeding 13.2 billion KRW and achieved a high operating profit margin of 25%.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

Seo Yoo-jin, CEO of Jinsystem, stated, “We hope that the platform-based COVID-19 testing system can help overcome the current health crisis in the Indian market, which is facing great difficulties due to the recent spread of COVID-19.”


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing